2015), Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls, which has been published in final form at Scientific category: Key point  Myeloproliferative neoplasm patients have significantly higher symptom burden and lower overall quality of life when compared to that of the general population. Abstract Rationale: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but current symptom assessment tools have not been validated compared to the general population. Objectives: The MPN-Symptom Assessment Form (MPN-SAF), a reliable and validated clinical tool to assess MPN symptom burden, was administered to MPN patients (n=106) and, for the first time, population controls (n=124) as part of a UK pilot case-control study. Mean symptom scores were compared between patients and controls adjusting for potential confounders. Mean patient scores were compared to data collected by the Mayo Clinic, USA on 1,446 international MPN patients to determine patient group representativeness.
Introduction
The BCR-ABL negative classic myeloproliferative neoplasms (MPNs) which include polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases with an estimated incidence rate of 0.84, 1.03 and 0.47 per 100,000, respectively 1 The aim of this study was to determine, for the first time, if the MPN-SAF was able to discriminate between symptom burden experienced by MPN patients and that reported in the general population.
It also aimed to compare symptom burden and overall quality of life reported by MPN patients in the UK to those reported internationally.
Methods

MOSAICC pilot case-control study
The pilot MOSAICC (Myeloproliferative Neoplasms: An In-depth Case-Control) study aimed to identify appropriate methodological approaches to roll-out a UK-wide case-control study of MPNs.
MPN-UK patients were recruited from two sites: Belfast City Hospital, Belfast, Northern Ireland and University Hospital Southampton NHS Foundation Trust, Southampton, England. Eligible patients were classified according to the WHO diagnostic criterion 9 and identified by their lead consultant (MFMcM and ASD). A study information pack was provided which contained a consent form, study information booklet and the MPN-SAF. Patients were asked to recruit non-blood relative or friend controls to the study by providing them with information flyers. Age (5-year age band) and gender frequency-matched General Practice controls were recruited by sending a study information pack with self-complete MPN-SAF to all controls. The completed MPN-SAFs were returned in pre-paid envelopes. Ethical approval was obtained from the Office for Research Ethics Committee, Northern Ireland (OREC-NI). MPN-UK patients were receiving standard treatment regimens.
Mayo Clinic
Detailed information on a subset of the patients presented in this paper are described in detail elsewhere 5, 10 . Briefly, 1,446 MPN-patients were prospectively recruited to participate in an assessment of symptom burden at the time of an office visit. Patients were accrued in academic, private, and government-funded medical facilities from approximately November 2009 to January 2011. The patient survey included questions on demographic and disease-related variables including symptom burden assessment via the MPN-SAF. This study included participants from Argentina, France, Germany, Italy, the Netherlands, United Kingdom, United States [including Puerto Rico], Spain, Sweden, and Uruguay and was administered in seven languages. Once collected by our team of international collaborators, data was de-identified and transferred to Mayo Clinic for compilation and analysis.
MPN-SAF
The MPN-SAF is an adaptation of the Myelofibrosis-SAF which includes symptoms common to PV and ET patients based on an internet survey. The MPN-SAF has questions regarding: fatigue (current, usual, worst in last 24 hours), measured on a scale from 0 (absent) to 10 (worstimaginable), and how fatigue affects general activity, mood, walking ability, normal work, relations with other people and enjoyment of life, measured on a scale of 0 (Does not interfere) to 10 (Completely interferes). In addition questions on early satiety (filling up quickly when you eat), abdominal pain, abdominal discomfort, inactivity, problems with headaches, concentration, dizziness/vertigo/light headedness, numbness/tingling, difficulty sleeping, depression or sad mood, problems with sexual desire or function, cough, night sweats, pruritis (itching), bone pain (diffuse not joint pain or arthritis), fever (>37.8 oC ), unintentional weight lost in last 6 months were measured on a scale from 0 (absent) to 10 (worst-imaginable). Finally participants were asked to rate their overall quality of life on a scale from 0 (As good as it can be) to 10 (As bad as it can be).
Statistical Analysis
Symptom prevalence was calculated for all variables by dividing the number of patients reporting a score above 1 by all respondents. Mean scores were calculated for each symptom variable and standard deviations calculated. Regression analyses were conducted initially comparing symptom scores in MPN-UK patients and controls to determine, for the first time, the extent of MPN symptoms compared to the general population. MPN-UK cases were then compared to MPN-Mayo patients, adjusting for age (continuous) and gender, to evaluate the representativeness of the MOSAICC study MPN patients.
Symptom and overall quality of life scores were categorised into three groups [0 (baseline), 1-5 and 
Results
Two hundred and thirty surveys were completed by MOSAICC study participants (106 MPN-UK patients, 124 controls) and 1,446 surveys completed by MPN-Mayo patients after excluding those without age or gender information available (n=24). Overall, more female MPN-UK patients, UK controls and MPN-Mayo patients (60.4%, 62.1% and 54.7%, respectively) than males completed the survey. MPN-UK patients, UK controls and MPN-Mayo patients were of a similar mean age (62.2. 60.8 and 63.2 years, respectively).
MPN-UK patients were more likely than controls to report a higher score for all symptoms, with the exception of fever, when analyses were adjusted for age and gender, Table 1 . Conversely, both patient groups reported similar symptom scores for most variables, Figure 1 , with patients from the Mayo Clinic study more likely to report early satiety when adjusted for age and gender than MPN-UK patients (p=0.046) , Table 1 .
When comparing symptom burden in MPN-UK patients and controls MPN-UK patients were more likely than controls to experience worse fatigue, fatigue affecting general activity, mood, walking ability and normal work, enjoyment of life, abdominal pain and discomfort, inactivity, headaches, lack of concentration, dizziness, numbness, difficulty sleeping, depression, sexual problems, cough, night sweats, pruritus, bone pain, fever, weight loss and overall quality of life, Figure 2/Table 2. All symptoms showed an increasing trend per unit increase in score with the exception of relations with other people, Table 2 .
Of the MPN subtypes PV patients were more likely to report difficulty with lack of concentration, sleeping, depression, sexual problems, pruritus and lower overall quality of life than ET and PMF patients but differences did not reach statistical significance (data not shown), Figure 1 . ET patients had the highest burden for mood, relations with other people, headaches and bone pain. PMF patients displayed the highest burden for fatigue, fatigue affecting general activity, walking, normal work and enjoyment of life, satiety, abdominal discomfort, inactivity, dizziness, numbness, cough, night sweats, fever and weight loss, Figure 1 . The mean symptom score for cough was significantly higher in PMF patients than PV (p=0.039) or ET (p=0.024) patients. Symptom scores for fever were also higher in PMF than PV patients (p=0.050).
Within the pilot MOSAICC study female MPN patients displayed the worst symptom burden for all variables with the exception of sexual problems which were more common in male MPN patients, Figure 2 . Female MPN patients were significantly more likely than male MPN patients to report higher mean scores for fatigue, mood, early satiety, headaches, lack of concentration, dizziness, difficulty sleeping, depression and night sweats, Table 3 . Female MPN patients were significantly more likely than female controls to report higher symptom burden for all variables except fever and for overall quality of life. Quality of life in male MPN patients did not differ to that of male controls and there were fewer significant differences compared with females. Male and female controls did not report different symptom scores for any of the variables or overall quality of life, Table 3 .
Discussion
The MPN-SAF is a clinically validated tool for assessing symptom burden in patients with MPNs.
For the first time we report the extent of symptoms in MPN patients compared to the general population demonstrating the significant burden experienced by MPN patients, particularly females.
All symptoms assessed were more common in MPN patients than controls, with the expectation of 'relations with other people', after adjusting for potential confounders. Female MPN patients also However, male MPN-UK patients and male controls reported similar levels of fatigue when adjusted for potential confounders while MPN-UK women reported significantly more fatigue that female controls. Further evaluation of these gender differences, particularly in relation to treatment, is warranted. In a previous study male patients scored higher than females for experiencing sexual problems and weight loss 15 . While sexual problems appeared more common in male than female MPN patients in the MOSAICC study no significant association was observed. This could be due to the limited sample size included in the pilot study and will be further explored in the planned UK-wide study. However, sexual problems and weight loss were significantly more common in male MPN-UK patients than controls. which is assessing the effects of the JAK2 inhibitor Ruxolitinib versus placebo and COMFORT-II evaluating Ruxolitinib versus best available treatment in PMF patients, have shown marked improvement in overall quality of life with improvements in pruritus, night sweats, abdominal discomfort, and bone pain 21, 22 . However, the symptoms remain higher than those reported by controls within this study demonstrating the need for more effective treatments. Additionally, Ruxolitinib, has a number of common side-effects which limit their use. Ruxolitinib is now licensed by the Federal Drug Administration in the USA for Hydroxyurea refractory or intolerant PV. Investigation of alternative strategies to alleviate symptoms including fatigue, such as physical activity programmes, should be evaluated.
The strengths of this study include the inclusion of a population control group reporting symptoms using the validated MPN-SAF questionnaire. This has enabled us to investigate for the first time the diverse range of symptoms covered by the MPN-SAF in a non-diseased group. However, this was a pilot investigation and as such the sample size is limited. Expanding the study to a larger number of patients and controls will provide a more robust assessment of the discriminatory ability of the questionnaire. Ability to adjust for potential confounding variables such as co-morbidities, smoking and alcohol consumption have enabled a more accurate comparison of MPN symptom burden with that of controls. Similarities in all symptoms between MPN-UK and MPN-Mayo groups, with the exception of early satiety, demonstrate the usefulness of this questionnaire in symptom evaluation.
The study does recognise the potential limitation of self-reporting bias which may differ between patients and controls. While the study was only administered on one occasion elements of the MPN-SAF (including fatigue, early satiety, abdominal pain, abdominal discomfort, inactivity, headache, concentration, dizziness, numbness, difficulty sleeping, depression, sexual problems, night sweats, pruritus, and bone pain) have been shown to have good correlation on repeat measurement 5 . MPN patients included in the pilot MOSAICC study were incident and prevalent cases (mean duration since diagnosis was 5 years) and evaluation of symptom burden by time since diagnosis in comparison to the normative population is warranted.
In conclusion, this study, for the first time compares symptom burden in MPN patients with that of controls and acknowledges the manifestation of symptoms and burden in MPN patients and its effect on overall quality of life. Furthermore, this study supports the need for quality of life assessment in clinical practice and clinical trial settings to manage and reduce disease burden and improve overall patient quality of life. Fatigue is the most prevalent symptom experience, particularly in females, and is an important factor for development of future treatment strategies.
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